未知生产厂商
DLO6002 is developed by Summit Corporation and is in phase I of clinical trials for the treatment of Parkinson's disease.
DLO6002 is developed by Summit Corporation and is in phase I of clinical trials for the treatment of Parkinson's disease.
Investigated for use/treatment in parkinson's disease.
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物,而非通用名;且专利申请在提交约 18 个月后才公开,较新的药物可能尚未出现在这里。